BI Asset Management Fondsmaeglerselskab A S Makes New Investment in Cencora, Inc. (NYSE:COR)

BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 7,351 shares of the company's stock, valued at approximately $1,652,000.

Other large investors have also made changes to their positions in the company. Passumpsic Savings Bank raised its position in Cencora by 4.9% in the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company's stock worth $1,455,000 after purchasing an additional 304 shares in the last quarter. Virtu Financial LLC raised its position in Cencora by 112.2% in the third quarter. Virtu Financial LLC now owns 10,227 shares of the company's stock worth $2,302,000 after purchasing an additional 5,407 shares in the last quarter. World Investment Advisors LLC acquired a new position in Cencora in the third quarter worth about $4,072,000. Arvest Bank Trust Division acquired a new position in Cencora in the third quarter worth about $218,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Cencora in the third quarter worth about $566,000. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Price Performance

Shares of COR stock traded up $3.66 on Friday, reaching $286.05. The company had a trading volume of 1,815,757 shares, compared to its average volume of 1,522,859. The business's 50-day moving average is $268.09 and its 200 day moving average is $249.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock has a market capitalization of $55.47 billion, a PE ratio of 40.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Analyst Ratings Changes

Several analysts have recently weighed in on COR shares. Morgan Stanley set a $288.00 price objective on shares of Cencora in a report on Tuesday, April 15th. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Wells Fargo & Company increased their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Finally, Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $284.55.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock valued at $13,580,967 in the last quarter. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.